drugset / Trial / NCT02327546

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

NCT02327546

Phase 1 Completed 10 enrolled Akebia Therapeutics
RandomizedCrossoverOpen-labelOther

Summary

The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.

Timeline

Start
2014-12
Primary completion
2014-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferrous Sulfate Diagnostic / imaging agent 325 mg
Subject Vadadustat Small molecule 450 mg

Indications

No indication recorded.